Profusa Signs Non-Binding Term Sheet to Acquire $111M-Revenue Diagnostics Company, Overhauls Leadership
PFSA is trading near its 52-week low of $1.6 (1.9% below the low) on light trading volume (0.1× avg).
Summary
Profusa announced a non-binding term sheet to acquire a diagnostics company with ~$111M in estimated 2025 revenue, a leadership overhaul, and a planned $7M convertible note financing. The deal could be transformative but carries significant dilution and execution risk.
Key Events · M&A and Partnerships · PFSA
-
Transformative Acquisition Announced
Profusa signed a non-binding term sheet to acquire a commercial-stage health diagnostics and toxicology testing company with estimated 2025 net revenues of approximately $111 million, aiming to create a publicly traded diagnostics platform.
-
Consideration Structure
Profusa will issue shares equal to 19.99% of its outstanding common stock immediately, with the remainder in non-voting convertible preferred stock convertible upon shareholder approval, potentially resulting in significant dilution.
-
Concurrent $7M Convertible Note Financing
Profusa expects to close approximately $7 million in convertible notes with a 12-month term, 9% original issue discount, and 7% interest (18% upon default), reflecting distressed financing terms.
-
Leadership Overhaul
Jack Stover appointed Executive Chairman and CEO; Ben Hwang transitions to President and resigns from the board; Liviu Goldenberg appointed as independent director, bringing 30+ years of operational and governance experience.
Analysis · PFSA · Industrial Applications And Services
A micro-cap digital health company trading near its 52-week low and facing going-concern risks, Profusa has signed a non-binding term sheet to acquire a commercial-stage diagnostics company with estimated 2025 net revenues of approximately $111 million. The deal would transform Profusa into a publicly traded diagnostics platform with national CLIA-certified labs and recurring revenue. Consideration includes issuing 19.99% of Profusa's outstanding common shares immediately, with the remainder in convertible preferred stock requiring shareholder approval — a structure that could result in massive dilution for existing holders. Concurrently, the company expects to raise $7 million in convertible notes with a 9% original issue discount and 7% interest (18% upon default), terms that reflect its distressed position. Leadership has been overhauled: Jack Stover becomes Executive Chairman and CEO, Ben Hwang moves to President and resigns from the board, and Liviu Goldenberg joins as an independent director. While the term sheet is non-binding and subject to due diligence, definitive agreements, and shareholder approval, the announcement signals a dramatic strategic pivot that could either rescue the company or further dilute shareholders if the deal collapses.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PFSA was trading at $1.57 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $906.3K. The 52-week trading range was $1.60 to $4,162.51. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.